Kyowa Kirin’s Burosumab Hits Primary Endpoint in Multinational PIII Study in XLH Children including Japan

Kyowa Kirin’s burosumab, an anti-FGF23 monoclonal IgG1 antibody, met its primary endpoint in a multinational PIII study in children with X-linked hypophosphatemia (XLH) including Japanese patients, the company and its US partner Ultragenyx Pharmaceutical said jointly on May 17. In...read more